Korro Bio Inc
KRRO14.540USD
+0.690+4.98%
交易中 （美東）報價延遲15分鐘
136.51M總市值
虧損本益比TTM
關於 Korro Bio Inc 公司
Korro Bio, Inc. 是一家生物製藥公司。該公司發現、開發和商業化基於編輯核糖核酸 (RNA) 的基因藥物，從而能夠治療罕見和高度流行的疾病。該公司正在生成一系列差異化項目，旨在利用人體天然的 RNA 編輯過程來實現精確但短暫的單鹼基編輯。通過編輯 RNA 而不是 DNA，該公司正在擴大基因藥物的覆蓋範圍。其寡核苷酸促進的 RNA 編輯 (OPERA) 是 RNA 編輯的基礎平臺，旨在通過提供可以靶向特定 RNA 序列的寡核苷酸嚮導來編輯體內 RNA。該公司的首個開發候選藥物 KRRO-110 正在開發中，作爲 Alpha-1 抗胰蛋白酶缺乏症 (AATD) 的潛在治療方法，具有改變疾病並提供差異化治療選擇的潛力。
公司簡介
公司代碼KRRO
公司名稱Korro Bio Inc
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
員工數量104
證券類型Ordinary Share
年結日Oct 03
公司地址One Kendall Square. Building 600-700
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02139
電話16174681999
網址https://www.korrobio.com/
公司代碼KRRO
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Mr. Vineet Agarwal
Mr. Vineet Agarwal
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Katharine (Kate) Knobil, M.D.
Dr. Katharine (Kate) Knobil, M.D.
Independent Director
Independent Director
--
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
收入明細
FY2025Q1
FY2024
暫無數據
地區USD
名稱
營收
佔比
United States
2.55M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Deep Track Capital LP
9.31%
AllianceBernstein L.P.
7.25%
Fidelity Management & Research Company LLC
6.85%
Other
52.86%
持股股東
持股股東
佔比
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Deep Track Capital LP
9.31%
AllianceBernstein L.P.
7.25%
Fidelity Management & Research Company LLC
6.85%
Other
52.86%
股東類型
持股股東
佔比
Investment Advisor
29.04%
Hedge Fund
27.68%
Venture Capital
23.84%
Investment Advisor/Hedge Fund
21.97%
Corporation
5.75%
Research Firm
0.99%
Individual Investor
0.42%
Private Equity
0.34%
Bank and Trust
0.09%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
185
10.37M
110.42%
-208.38K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
2023Q2
235
150.53K
21.10%
-156.09K
2023Q1
266
144.14K
20.36%
-179.94K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Atlas Venture
1.14M
12.11%
--
--
Apr 15, 2025
New Enterprise Associates (NEA)
1.09M
11.62%
--
--
Mar 31, 2025
Deep Track Capital LP
874.61K
9.31%
--
--
Mar 31, 2025
AllianceBernstein L.P.
680.52K
7.25%
-25.28K
-3.58%
Mar 31, 2025
Fidelity Management & Research Company LLC
643.27K
6.85%
+1.53K
+0.24%
Mar 31, 2025
Driehaus Capital Management, LLC
582.45K
6.2%
+87.54K
+17.69%
Mar 31, 2025
Platanus Investment LLC
540.16K
5.75%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
520.89K
5.55%
+26.89K
+5.44%
Mar 31, 2025
Invus Public Equities Advisors, LLC
418.83K
4.46%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
407.81K
4.34%
-7.23K
-1.74%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Health Innovation Active ETF
0%
iShares Russell 3000 ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
SPDR Portfolio MSCI Global Stock Market ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
iShares Health Innovation Active ETF
佔比0%
iShares Russell 3000 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
公告日期
類型
比率
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
Nov 03, 2023
Merger
50<1
